In 1,670 patients at high risk of restenosis, from 3 to 7 years, target lesion failure was 6.7% with bioresorbable scaffolds vs 5.9% with everolimus-eluting stents (HR 1.14, P=0.53), not superior; repeat revascularisation was higher (4.4% vs 2.2%).
RCTn = 1,670
Smits et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial